Active Ingredient
Omeprazole 40mg per vial for intravenous administration
What Risek IV Injection 40mg Is Used For
Risek IV Injection 40mg is a prescription-only intravenous formulation of omeprazole, a Proton Pump Inhibitor (PPI), indicated for short-term treatment of up to 5 days in adult patients for whom oral administration is not feasible or appropriate. This medication is exclusively administered by or under the direct supervision of a qualified healthcare professional in a clinical setting. It is indicated for:
- Gastro-Esophageal Reflux Disease (GERD), including severe erosive esophagitis requiring parenteral acid suppression when the patient cannot take oral medication
- Active gastric and duodenal ulcers, including complicated or bleeding ulcers requiring urgent and reliable acid suppression that cannot be achieved through oral therapy
- Zollinger-Ellison syndrome, a rare condition caused by gastrin-secreting tumors that drive excessive and uncontrolled gastric acid production, requiring potent and continuous acid suppression
- Prevention of acid aspiration during general anesthesia, where gastric acid suppression before surgical procedures reduces the risk of pulmonary aspiration injury if gastric contents enter the airway
- Upper gastrointestinal bleeding associated with peptic ulceration, where intravenous acid suppression is critical for clot stabilization and prevention of rebleeding in the acute setting
- Stress ulcer prophylaxis in critically ill patients requiring parenteral nutrition or those who cannot tolerate enteral feeding
Omeprazole works by irreversibly blocking the hydrogen-potassium adenosine triphosphatase enzyme system, the proton pump, in the gastric parietal cells responsible for acid secretion. When administered intravenously, omeprazole bypasses the gastrointestinal tract entirely, ensuring complete and predictable bioavailability regardless of the patient's gastrointestinal function, motility, or absorptive capacity. This is the primary clinical advantage of the intravenous formulation over oral preparations. Intravenous omeprazole achieves therapeutic plasma concentrations more rapidly than oral formulations, providing faster onset of acid suppression that is particularly critical in acute upper gastrointestinal bleeding where every hour of elevated gastric pH significantly improves hemostatic outcomes. Clinical studies demonstrate that intravenous omeprazole administered as a high-dose bolus followed by continuous infusion can maintain gastric pH above 6, the level necessary for optimal platelet aggregation and clot stability, for sustained periods in patients with actively bleeding peptic ulcers.
Important Safety Information
Who Should NOT Receive Risek IV Injection 40mg
Do not administer this medication to patients who have a known hypersensitivity or anaphylactic reaction to omeprazole, any other substituted benzimidazole proton pump inhibitors including lansoprazole, pantoprazole, rabeprazole, or esomeprazole, or any excipients in the intravenous formulation, are concurrently receiving rilpivirine-containing antiretroviral regimens or nelfinavir for HIV treatment as omeprazole significantly reduces their plasma concentrations and therapeutic effectiveness to clinically dangerous levels, have been confirmed to have no indication for acid suppression therapy, or for whom intravenous access cannot be safely established or maintained.
Serious Warnings and Precautions
For Clinical Use Only: Risek IV Injection 40mg must only be prepared, administered, and monitored by trained healthcare professionals in an appropriate clinical environment equipped for management of potential adverse reactions including anaphylaxis. This medication must never be self-administered outside of a supervised clinical setting.
Transition to Oral Therapy: Intravenous omeprazole is indicated for short-term use of up to 5 days only. As soon as the patient's clinical condition permits oral intake, transition to an appropriate oral omeprazole or PPI formulation should occur promptly. Prolonged intravenous PPI use beyond the clinically necessary period is not appropriate and increases the risk of complications associated with extended parenteral therapy.
Masking of Serious Gastrointestinal Pathology: Powerful intravenous acid suppression can rapidly abolish symptoms of serious underlying conditions including gastric malignancy. In patients receiving Risek IV for upper gastrointestinal bleeding or ulcer management, endoscopic evaluation must not be deferred solely because symptoms have improved following acid suppression. Endoscopic assessment remains essential for definitive diagnosis, risk stratification, hemostatic intervention where required, and exclusion of malignancy. Alarm features including unexplained weight loss, progressive dysphagia, persistent vomiting, hematemesis, melena, or palpable abdominal masses must be formally investigated regardless of symptomatic response to treatment.
Hypersensitivity and Anaphylaxis: Serious hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, and severe cutaneous reactions have been reported with intravenous PPI administration. The risk of serious immediate hypersensitivity reactions is higher with intravenous than oral formulations due to the direct systemic delivery. Healthcare providers must be prepared to manage anaphylaxis immediately, with epinephrine, antihistamines, corticosteroids, airway management equipment, and resuscitation facilities readily available during and after administration. If any signs of hypersensitivity develop during infusion, the medication must be stopped immediately.
Injection Site Reactions: Intravenous administration of omeprazole can cause local reactions at the injection site and along the vein, including thrombophlebitis, pain, erythema, and swelling. The prepared solution must be administered according to the recommended dilution and infusion rate specifications to minimize the risk of local irritation and venous damage. Proper intravenous technique, including adequate dilution, appropriate infusion rate, and regular assessment of the injection site, is essential.
Hypomagnesemia: Prolonged PPI therapy, including intravenous administration, is associated with clinically significant reductions in serum magnesium. In critically ill patients or those already at risk of electrolyte imbalances, hypomagnesemia can cause life-threatening cardiac arrhythmias, neuromuscular irritability, seizures, and tetany. Serum magnesium should be monitored in patients receiving extended intravenous PPI therapy and in those concurrently receiving digoxin, diuretics, or other medications that affect magnesium balance.
Electrolyte Monitoring in Critical Care: Critically ill patients receiving Risek IV Injection frequently have pre-existing electrolyte disturbances, organ impairment, and complex medication regimens that increase the risk of drug interactions and adverse effects. Regular monitoring of serum electrolytes, renal function, and hepatic function is essential during the course of intravenous PPI therapy in this patient population.
Clostridium difficile Risk: Intravenous PPI therapy is associated with an increased risk of Clostridium difficile-associated diarrhea, particularly in critically ill patients who are also receiving antibiotics. Healthcare providers should maintain a high index of suspicion for Clostridium difficile infection in patients who develop new or worsening diarrhea during or following treatment.
Hepatic Impairment: Omeprazole is extensively metabolized by hepatic CYP enzymes. In patients with moderate to severe hepatic impairment, omeprazole clearance is significantly reduced, resulting in substantially elevated and prolonged plasma drug concentrations. The intravenous dose must be reduced and carefully titrated in patients with significant liver disease. Liver function should be monitored in patients with known hepatic impairment receiving this medication.
Zollinger-Ellison Syndrome Management: Patients with Zollinger-Ellison syndrome typically require higher doses of omeprazole to achieve adequate acid suppression due to the ongoing drive of gastrin-mediated acid hypersecretion. Dosing must be individualized based on gastric acid output measurements and clinical response. Regular reassessment of acid secretory status is necessary to ensure ongoing therapeutic adequacy.
Anesthesia and Surgical Use: When used for prevention of acid aspiration before general anesthesia, Risek IV must be administered within the timing parameters established by the surgical and anesthesia team's protocol. Adequate preoperative acid suppression requires sufficient lead time before anesthetic induction. The anesthesia team must be informed of all medications the patient is receiving that may affect gastric pH, motility, or volume.
Notify the attending medical team or call for emergency assistance immediately if the patient develops signs of anaphylaxis including urticaria, bronchospasm, hypotension, or cardiovascular collapse during or following infusion, experiences severe injection site reactions including extravasation or signs of chemical phlebitis, develops signs of seriously low magnesium including cardiac arrhythmias, severe muscle weakness, tetany, or seizures, shows signs of Clostridium difficile infection including severe watery or bloody diarrhea with systemic features, develops signs of hepatic dysfunction, or experiences any unexpected or concerning change in clinical status during the course of treatment.
Consult Senior Medical Staff or Specialist Before Use In Patients Who Have:
Severe hepatic impairment or active liver disease requiring dose adjustment and close monitoring, severe renal impairment where excretion of metabolites may be affected, known hypersensitivity to any PPI or benzimidazole derivative requiring alternative acid suppression strategies, concurrent antiretroviral therapy particularly with rilpivirine or nelfinavir where omeprazole is contraindicated, active cardiovascular disease where hypomagnesemia from PPI therapy poses additional arrhythmia risk, concurrent digoxin or diuretic therapy amplifying hypomagnesemia risk, established osteoporosis where additional bone loss risk from PPI therapy requires management, are pregnant where the risk-benefit balance of intravenous PPI therapy must be carefully evaluated, are receiving concurrent medications with clinically significant interactions with omeprazole, have a history of Clostridium difficile infection particularly if also receiving antibiotics, or have complex comorbidities requiring careful individualization of acid suppression therapy.
Common Side Effects
In the clinical setting, Risek IV Injection 40mg is generally well-tolerated when correctly prepared and administered. However, patients and healthcare providers should be aware that some individuals may experience injection site reactions including pain, erythema, swelling, and thrombophlebitis, headache, nausea or vomiting, diarrhea or constipation, abdominal discomfort, dizziness, elevated liver enzymes on blood tests, and skin rash. In critically ill patients receiving concomitant medications, attributing specific side effects to omeprazole alone may be clinically challenging.
Serious adverse effects requiring immediate clinical intervention include anaphylaxis and severe hypersensitivity reactions, severe injection site reactions including extravasation and chemical phlebitis, clinically significant hypomagnesemia causing cardiac arrhythmias or neuromuscular complications, severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, acute interstitial nephritis causing progressive renal impairment, significant hepatotoxicity, Clostridium difficile-associated colitis, and subacute cutaneous lupus erythematosus in patients on prolonged therapy.
Drug Interactions
The intravenous route of administration ensures complete systemic bioavailability of omeprazole, which may intensify drug interactions compared to oral formulations where absorption can be variable. Healthcare providers must conduct a thorough medication review before initiating Risek IV Injection in any patient. Clinically significant interactions include those with rilpivirine and nelfinavir for HIV treatment where the combination is absolutely contraindicated, clopidogrel for antiplatelet therapy where omeprazole substantially reduces its active metabolite formation through CYP2C19 inhibition and may compromise cardiovascular protection in high-risk patients, methotrexate where high-dose PPI therapy significantly increases methotrexate plasma levels and the risk of serious hematological and mucosal toxicity, warfarin and other anticoagulants where omeprazole can enhance anticoagulant effect and increase bleeding risk requiring more frequent INR monitoring, antifungal agents including ketoconazole, itraconazole, and posaconazole whose absorption from any concurrent oral doses depends on gastric acidity, atazanavir and other HIV protease inhibitors whose absorption is significantly reduced by acid suppression, tacrolimus and other calcineurin inhibitors where omeprazole may increase blood levels particularly in patients who are poor CYP2C19 metabolizers, phenytoin where omeprazole inhibits its hepatic metabolism potentially causing toxicity, digoxin where altered gastric pH and possible metabolic interactions can affect serum levels, iron preparations and vitamin B12 where intravenous omeprazole may impair absorption of any oral supplements given concurrently, erlotinib and certain other targeted cancer therapies whose bioavailability is pH-dependent, and any other medications being administered concurrently in the inpatient setting that may interact with omeprazole's effects on gastric pH or hepatic enzyme activity.
How Risek IV Injection 40mg Is Administered
Risek IV Injection must only be prepared and administered by trained healthcare professionals following established institutional protocols and the manufacturer's specific preparation instructions. It must never be self-administered.
Preparation: The lyophilized powder must be reconstituted with the appropriate volume of compatible diluent as specified in the manufacturer's instructions before administration. The reconstituted solution must be visually inspected for particulate matter and discoloration before use. Do not use if the solution is cloudy, discolored, or contains visible particles. Prepared solutions must be used within the timeframe specified in the product information and must not be stored beyond this period.
Standard Dosing: For most indications in adults, the recommended dose is 40mg administered once daily by intravenous infusion. For acute upper gastrointestinal bleeding, high-dose protocols may involve an initial 80mg bolus followed by continuous infusion at 8mg per hour for 72 hours, after which standard once-daily dosing may continue until transition to oral therapy is possible. For Zollinger-Ellison syndrome, dosing must be individually titrated based on gastric acid output measurements and clinical response. For anesthesia prophylaxis, the dose and timing are determined by the anesthesia protocol of the institution.
Administration: Administer by slow intravenous infusion over the time period specified in the prescribing information, typically 20-30 minutes for bolus doses. Do not administer as a rapid intravenous bolus injection. Flush the intravenous line with compatible solution before and after administration to prevent incompatibility with other medications. Do not mix with or administer through the same line as other medications unless compatibility has been specifically confirmed.
Duration: Treatment with intravenous omeprazole should not exceed 5 days unless there are exceptional circumstances requiring continuation under specialist supervision. Transition to appropriate oral therapy should occur as soon as clinically feasible.
Based on our pharmacists' clinical observations, the most critical aspects of safe and effective Risek IV Injection administration are strict adherence to reconstitution and dilution protocols, correct infusion rate to minimize venous irritation, thorough medication reconciliation before administration to identify and manage drug interactions, prompt recognition and management of injection site complications, and early planning for transition to oral therapy to limit the duration of parenteral treatment. In the management of acute upper gastrointestinal bleeding, maintaining gastric pH above 6 through high-dose continuous infusion protocols in the first 72 hours significantly reduces rebleeding rates and the need for repeat endoscopic intervention, underscoring the importance of correct dosing and uninterrupted infusion during this critical window.
What Healthcare Providers and Patients Need to Know
Acute Upper Gastrointestinal Bleeding: Intravenous omeprazole plays a critical role in the pharmacological management of peptic ulcer bleeding following endoscopic hemostatic therapy. Achieving and maintaining a gastric pH above 6 prevents premature clot dissolution by reducing pepsin activity and optimizing platelet aggregation at the bleeding site. High-dose intravenous PPI therapy administered continuously in the 72 hours immediately following endoscopic hemostasis has been shown in multiple clinical trials to significantly reduce rebleeding rates, the need for surgical intervention, and mortality. The clinical benefit is most pronounced in patients with high-risk endoscopic stigmata including active arterial bleeding, a visible vessel, or an adherent clot.
Zollinger-Ellison Syndrome: Managing acid hypersecretion in Zollinger-Ellison syndrome with intravenous omeprazole requires careful titration against measurable gastric acid output. The therapeutic target is typically to reduce basal acid output to below 10 mEq per hour in patients without prior gastric surgery. Doses significantly higher than the standard 40mg may be required. When transitioning to oral therapy, equivalent or higher oral doses must be carefully calculated and gastric acid output reassessed to confirm adequacy of the oral regimen before discharge.
Stress Ulcer Prophylaxis in Critical Care: The use of intravenous PPIs for stress ulcer prophylaxis in critically ill patients should be targeted to those at highest risk, including patients with mechanical ventilation for more than 48 hours, coagulopathy, severe head injury, major burns, or multiple organ failure. Indiscriminate use of PPI prophylaxis in all ICU patients increases the risk of Clostridium difficile infection, hospital-acquired pneumonia, and drug interactions without proven benefit in lower-risk patients. Prophylaxis should be discontinued as soon as the patient's risk factors resolve or when enteral nutrition is well established.
Pregnancy and Breastfeeding: The use of intravenous omeprazole during pregnancy should be limited to situations where oral therapy is not feasible and the clinical indication is compelling. The risk-benefit assessment must be made by the treating physician in consultation with the patient. Omeprazole passes into breast milk and the implications for nursing infants from intravenous administration must be discussed with the patient's care team.
Storage and Handling Instructions
Store unreconstituted vials at room temperature below 25°C, protected from light and moisture. Keep in original packaging until immediately before preparation. Reconstituted solutions must be prepared in a clean environment following aseptic technique and used within the stability period specified in the product information. Do not use vials that show signs of damage, compromised seal integrity, or visible contamination. Dispose of unused portions of reconstituted solution and all sharps and clinical waste in accordance with institutional infection control and hazardous waste disposal protocols.
Manufacturer Information
[Manufacturer name and details would be inserted here based on your specific product]
Regulatory Status: Risek IV Injection 40mg is a prescription-only medication for administration exclusively in clinical settings by trained healthcare professionals. It is not available for self-administration or home use.
Medical Review Notice: This product information should be reviewed by a licensed physician or clinical pharmacist with experience in intravenous PPI therapy to ensure accuracy and compliance with current clinical guidelines and institutional protocols. Clinical use should be guided by current evidence-based guidelines for the management of upper gastrointestinal bleeding, Zollinger-Ellison syndrome, erosive esophagitis, and stress ulcer prophylaxis in critically ill patients.
Last Updated: [Date would be inserted here]